Ocular Therapeutix Stock Earns 81 RS Rating

Group 1 - Ocular Therapeutix (OCUL) stock has achieved a Relative Strength (RS) Rating of 81, indicating strong market leadership [1] - Syndax Pharmaceuticals has received an RS Rating upgrade, reflecting improved technical performance [3] - Krystal Biotech's RS Rating has risen to 86, showcasing its strengthening position in the market [3] Group 2 - Genmab has entered into an $8 billion deal to acquire Merus, a company focused on cancer treatments, indicating strategic growth in the oncology sector [3] - Halozyme Therapeutics has seen an improvement in its RS Rating, suggesting positive market sentiment [3] - Incyte's stock has declined after its 2025 outlook did not meet Wall Street's optimistic expectations, highlighting potential challenges [3]